Cardiovascular Dashboard
Cardiovascular hiddenness becomes clearer when sponsor class, phase structure, and stock are separated
The cardiovascular dashboard isolates family-specific sponsor mix, phase mix, and leading sponsors rather than folding them into an all-registry average.
Sponsor classes
Phases
Top sponsors
Family-specific stock
Dashboard The cardiovascular page separates sponsor mix, phase mix, and raw stock so the family does not collapse into a single score.
How to read the dashboard
Eligible older
26,062
Cardiovascular studies
No-results rate
75.0%
2-year no-results
Largest phase bucket
13,817
nan
Top sponsor stock
144
Assistance Publique - Hôpitaux de Paris
Sponsor-class rates
CARDIOVASCULAR SPONSOR CLASSES 2-year no-results rate by sponsor class within cardiovascular studies OTHER_GOV 96.2% NETWORK 92.2% OTHER 82.1% NIH 70.9% INDUSTRY 57.1% FED 43.1% OTHER_GOV remains near the top where present, but the broader cardiovascular burden is still shaped by the much larger OTHER and INDUSTRY blocks.
This is a family-specific rate view, so it should be read alongside the top-sponsor stock chart rather than as a standalone leaderboard.
Phase pattern
CARDIOVASCULAR PHASES 2-year no-results rate by phase inside the cardiovascular family PHASE1 83.6% EARLY_PHASE1 82.7% nan 81.6% PHASE2 | PHASE3 71.8% PHASE4 70.8% PHASE1 | PHASE2 66.1% PHASE3 59.5% PHASE2 58.9% PHASE1 is the quietest major phase inside the cardiovascular family on the no-results metric.
Phase structure matters because the family-level average can hide very different early-phase and late-phase behavior.
Largest sponsor stocks
CARDIOVASCULAR TOP SPONSORS Lead sponsors with the largest missing-results stock inside cardiovascular studies Assistance Publique - Hôpitaux de Paris 144 Yonsei University 138 Mayo Clinic 126 Riphah International University 121 Seoul National University Hospital 114 Boehringer Ingelheim 101 Novartis 99 Cairo University 93 Abbott Medical Devices 89 AstraZeneca 87 Assistance Publique - Hôpitaux de Paris carries the largest named missing-results stock in this family at 144 studies.
The top-sponsor chart makes the family-specific backlog concrete instead of leaving it as a single family-wide percentage.
Read Across Projects
Across The Series Each project isolates a different dimension of registry opacity, but the point is the contrast between them, not a single leaderboard.
Industry
CT.gov Industry Disclosure Gap
Industry-focused missing-results stock, sponsor backlogs, and structural sparsity inside CT.gov.
Sponsor Classes
CT.gov Sponsor-Class Hiddenness
Sponsor-class comparisons on rate, stock, and structural hiddenness rather than one flattened ranking.
Phases
CT.gov Phase Reporting Gap
Phase-by-phase disclosure gaps showing how silence changes along the development pathway.
Structural
CT.gov Structural Missingness
Field-level missingness across publication links, IPD statements, descriptions, and locations.
Visibility
CT.gov Evidence Visibility Gap
Results-plus-publication visibility states showing how many older trials are fully visible, partly visible, or ghosted.
Cohorts
CT.gov Completion Cohort Debt
Completion-era reporting debt showing how older eligible cohorts drift on no-results and ghost-protocol rates.
Conditions
CT.gov Condition Hiddenness Map
Keyword-classified therapeutic-area hiddenness mapping across common condition families.
Concentration
CT.gov Sponsor Backlog Concentration
Concentration and inequality analysis showing how much unresolved stock sits inside a thin sponsor slice.
Rule Eras
CT.gov Rule-Era Reporting Gap
Policy-era comparisons across pre-FDAAA, FDAAA, and later CT.gov completion cohorts.
PubMed Audit
CT.gov Publication Undercount Audit
Sample-based external PubMed NCT audit testing how often CT.gov no-link records hide an external paper trail.
Oncology
CT.gov Oncology Hiddenness
Oncology-specific CT.gov hiddenness showing where cancer-trial stock, phases, and sponsors still go quiet.
Metabolic
CT.gov Metabolic Hiddenness
Metabolic CT.gov hiddenness across obesity, diabetes, and related trial portfolios with large late-phase and NA stock.
Readout Cardiovascular is rank #2 among named condition families by eligible older stock. 75.0% of older cardiovascular studies lack posted results. 39.3% show neither results nor a linked publication. Assistance Publique - Hôpitaux de Paris carries the largest named missing-results stock at 144.